Would it be enough for GS-7340 to show better tolerability than Truvada or would it have to show better efficacy? I think if it is the latter, then it's a pretty high bar. Even showing better renal and bone outcomes would probably need a fairly long-term study.
Another possible threat to Gilead is if nuke-sparing regimens eventually become popular.
Market Data 
Markets 
AI
